The day-to-day running of the organisation and our licensing and inspection operations are managed by a small core team, which is split into four directorates and led by a Chief Executive.
Allan Marriott-Smith became Chief Executive of the HTA in July 2015. Allan joined the HTA in May 2009, most recently working as Director of Strategy and Quality where he had corporate responsibility for the strategic and business planning process, quality improvement and the regulation of living donation. Prior to that Allan had worked for a number of years as a government statistician at the UK Statistics Authority.
As the Chief Executive of the HTA, Allan is the Accounting Officer and is responsible for implementing the strategic plan of the organisation. This involves improving the efficiency and effectiveness of regulation, ensuring that the HTA has appropriate and productive relationships with its stakeholders, and leading and managing the skilled and dedicated workforce at the HTA. Allan is also responsible for ensuring that the HTA is governed effectively and provides good value for money.
Louise joined the HTA in October 2019 as the Director of Data, Technology & Development. Prior to joining the HTA she has held a number of senior roles across healthcare including seven years in regulation with the Care Quality Commission.
Louise enjoys the intellectual and creative challenge of developing and delivering innovative solutions in complex environments. Over the course of her career these innovations have been recognised through national awards and publications as well as driving change through policy and operational improvements.
As our Director of Data, Technology & Development, Louise’s responsibilities include leading the HTA’s transformation programme over the next two years, developing the use of data and the insight that it can offer to how the HTA regulates and exploring opportunities for the adoption and use of technology in support how the HTA operates.
Nicolette joined the HTA in June 2018 as our Director of Regulation. Previously, she was the Head of Regulatory Delivery for the Food Standards Agency and prior to this, she held a number of senior management roles within HMRC, Scottish Public Pensions Agency and Revenue Scotland.
Nicolette’s responsibilities include the oversight and management of the HTA’s delivery of a right-touch programme of licensing, inspection and incident reporting; targeting our resources where there is most risk to public confidence and patient safety. She also oversees our effective regulation of living organ donation.
As our Director of Regulation, Nicolette ensures we provide high quality advice and guidance in a timely way to support professionals, Government and the public in matters within our remit. She also makes sure we are consistent and transparent in our decision-making and regulatory action.
Richard joined the HTA following a career as a finance professional in central government with a civil service background, most recently with Oxleas NHS Foundation Trust and the Ministry of Justice.
From November 2016, he became Director of Finance and Resources at both the HTA and the Human Fertilisation and Embryology Authority (HFEA) and splits his time between the two organisations.
At the HTA, Richard is responsible for leading and developing the financial and IT systems needed to support the HTA to carry out its statutory functions, and the provision of other facilities and services, including legal advice. He oversees financial governance and leads on risk management, working with the Audit and Risk Assurance Committee to ensure the Authority has assurance that the HTA’s systems are effective and working to fulfil our remit and objectives. Richard drives forward the HTA’s efficiency work, determines licence fees each year and plays a key part in change management.
The professional Members of our Board come from medical and scientific backgrounds linked to our work, and the lay Members bring a wide range of business, commercial and public sector experience.
The work of the Board is varied and includes:
- Setting the strategic direction of the HTA;
- Monitoring progress against strategic objectives;
- Making decisions on policy issues of strategic importance;
- Challenging, scrutinising and monitoring the performance of the Senior Management Team;
- Approving and monitoring the communications strategy;
- Ensuring that the views of stakeholders are properly accounted for in decision making;
- Ensuring that resources are adequate to deliver the strategy and are used efficiently and effectively;
- Overseeing the remuneration arrangements for the Senior Management Team and staff;
- Participating in Audit Committee, Remuneration Committee and Members’ groups;
- Acting as a panel Member for certain decisions on living organ donation
Lynne is Chair of Sustrans and a trustee of The Welsh National Opera. She is also a Visiting Professor at the Business School (City, University of London), a Fellow Commoner of Lucy Cavendish College (University of Cambridge), and an Honorary Fellow of Cardiff University.
Until recently Lynne was Chair of Breast Cancer Now, and before that Deputy-Chair of the Canal and River Trust, Chair of Glandŵr Cymru (The Canal and River Trust in Wales), and was a non-executive director and Senior Independent Director at Cambridge University Hospitals NHS Foundation Trust.
She has held Chief Executive roles at The Royal Volunteering Service (RVS), The Charity Commission, The General Social Care Council, The Equal Opportunities Commission, and The Family Welfare Association.
Lynne has a long interest in regulation, and together with her former roles in regulation, has been a member of a number of Government "better regulation" initiatives, and chaired a working group on risk and regulation for the Cabinet Office.
Amanda is a governor of University College London Hospitals (UCLH) where she chairs both the UCLH Organ Donation Committee and the UCL/UCLH Biobank Ethical Review Committee. She has now been appointed as Non Executive Director at Whittingtin Health NHS Trust. She was a member of the UK Donation Ethics Committee from 2012 until it was wound up in 2016 and is also a lay member of the NHS Blood and Transplant’s National Organ Donation Committee. Amanda is a living organ donor, having donated a kidney to her husband in 2008. She is also a trustee of various charities and a magistrate.
A former police officer, Bill represented the Association of Chief Police Officers on several national bodies. Following that career he has held a number of public service roles which included the position of Non-Executive Director with the Welsh Government, being a member of its Audit and Risk Assurance Committee and chairing its Economy, Science and Natural Resources Audit and Risk Assurance Committee. He is currently a non-legal member of the Employment Tribunals for the Wales region.
Charmaine is currently Chief Operating Officer at the Institute of Cancer Research.
Originally trained as a biomedical scientist, she is passionate about improving human health and quality of life, and has held high-profile Executive and Non-Executive roles at institutions including the British Heart Foundation and Brain Research UK.
She is also currently a Trustee of the Cranfield Trust, and Governor of the Royal Marsden NHS Foundation Trust.
Charmaine joined the HTA as a Member for 3 years from 1 September 2019.
From 2007 till 2016, Lorna was Medical and Research Director of NHS Blood and Transplant (NHSBT). Prior to that, she spent 16 years as an academic consultant with the University of Cambridge/National Blood Service. She was a founder of the UK haemovigilance scheme SHOT and the NHSBT/MRC Clinical Studies Unit.
Her interests are in clinical trials and policy making on safety issues. Lorna chaired the Royal College of Pathologists’ Transfusion Medicine Committee from 2010-2014 and was Director of Publishing and Engagement from 2015-2019. She is a Fellow Commoner of Lucy Cavendish College, University of Cambridge.
Stuart is Chair of the Advisory Committee on Clinical Excellence Awards (ACCEA). He is a fully GMC registered physician, who trained in General Medicine and General Practice before gaining many years experience in senior leadership roles at Roche, GlaxoSmithKline, Norgine, Takeda and UCB. He is the Founder of Vermilion Life Sciences, which provides consultancy services to reduce the time and cost of medicines development to improve patient access.
Stuart is also a Board Trustee of the Faculty of Pharmaceutical Medicine, and has worked as an external ‘Champion' for the UK Government's Office for Life Sciences, Accelerated Access Review.
'Glenn Houston has 35 years experience of working in health and social care in Northern Ireland. He was Chief Executive of the Regulation and Quality Improvement Authority (RQIA) between 2009 and 2016. Glenn has held a number of other senior appointments at both director and Chief Executive level. He is currently a non-executive Director on the Board of the Northern Health and Social Care Trust and the Disclosure and Barring Service. He lives in County Down, Northern Ireland.
Sam is a Consultant Gynaecologist, Specialist in In-Vitro Fertilisation and Clinical Director of The Lister Fertility Clinic. He publishes and lectures regularly on many aspects of assisted conception and is particularly interested in women with reduced ovarian reserve and high follicle stimulating hormone. As well as consulting, Sam is a highly skilled gynaecological surgeon specialising in laparoscopic (keyhole) surgery and removal of fibroids (myomectomy). Sam has a keen interest in and is a leading expert on oocyte donation.
Andy is an emeritus professor at Newcastle University. After qualification as a clinical haematologist he developed a research programme in childhood leukaemia before becoming the Director of the Northern Institute for Cancer Research. He has a long-standing interest in the use of tissues for research and acted as the Designated Individual for the Newcastle University HTA research licence. He has served on several national grant awarding committees and currently serves on the scientific advisory board for the Bone Cancer Research Trust and the National Institute for Health Research Career Development, Senior Research and Transitional Research Fellowship panel.
Anthony is a practicing consultant renal physician at the Royal London Hospital where his special interest is in transplantation medicine. He is Professor of Renal and Transplantation Medicine at Barts and The London School of Medicine and Dentistry, Queen Mary University of London, and his research interests are mechanisms of rejection and attitudes to organ donation. Anthony is currently Dean for Education at Barts and The London School of Medicine and Dentistry. He trained in Glasgow, Oxford, London and Boston USA.
Gary is a former Professor of Innovation at Keele University Business School, where he led and established the Mercia Centre for Innovation Leadership.
His corporate career was in senior leadership roles in Financial Services and organisational development and transformation, most notably for Royal Bank of Scotland (RBS) and latterly as Managing Consultant at PA Consulting.
He has held a wide range of Vice Chair and non-executive director roles with NHS Trusts, a building society and in education. Gary joined the HTA as a Member for 3 years from 1 September 2019.
In addition to being qualified as a barrister and solicitor in Ontario, Canada, Penney is Professor of Law at the Dickson Poon School of Law and Co-Director of the Centre of Medical Law and Ethics at King’s College London. She is a member of the Clinical Ethics Committee of St Christopher’s Hospice, and from 2010-2016, she was a member of the UK Donation Ethics Committee.
From 2004 to 2016, she was Vice-Chair of the King's College London Research Ethics Committee. Penney is an invited member of the Working Group on Deceased Donation of the European Platform on Ethical, Legal and Psychological Issues in Transplantation (ELPAT), and was part of a small expert group which drafted recently published European guidance on the ethical, legal and psychosocial aspects of organ donation after circulatory death (DCD).
Since January 2020, Penney is on secondment to the Law Commission as the Commissioner for Criminal Law for a period of 5 years.